INS and Cognitive impairment: Notably, decreased insulin receptor function increases synaptic sensitivity to the binding of and dysfunction caused by Aβ18, and insulin and insulin-sensitizing therapy has been shown to be effective for cognition in mouse models of AD as well as in patients with mild cognitive impairment (MCI) or early AD18–22.